4-fluoro MDMB-BUTICA butanoic acid metabolite (Item No. 31106) is an analytical reference standard that is structurally similar to known synthetic cannabinoids. 4-fluoro MDMB-BUTICA butanoic acid metabolite is a potential metabolite of 4-fluoro MDMB-BUTICA (Item No. 31075) based on the published metabolism of 5-fluoro MDMB-PICA (Item No. 20803).{45804} At the time 4-fluoro MDMB-BUTICA butanoic acid metabolite (Item No. 31106) was made available for purchase, specific metabolism data had not been published. Contact us if updated information on this molecule is now available. This product is intended for research and forensic applications.
Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Please check regulation status before ordering; additionel fees can apply.
| Size | 1 mg, 5 mg |
|---|---|
| Shipping | dry ice |
| Molecular formula | C19H25FN2O3 |
| Smiles | O=C(N[C@H](C(O)=O)C(C)(C)C)C1=CN(CCCCF)C2=C1C=CC=C2 |
| Molecular weight | 348,4 |
| Custom code | 3822.19 |
| Formulation | A crystalline solid |
| Purity | ≥98% |
| UNSPSC code | 12352100 |
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.
Inositol hexakisphosphate kinase 2 (IP6K2) is a cytoplasmic kinase that catalyzes the conversion of IP6 to diphosphoinositol pentakisphosphate in the...
The Cayman COX Inhibitor Pack contains a combination of frequently used cyclooxygenase (COX) inhibitors. Each kit contains aspirin, the archetype...
GST-tag Polyclonal Antibody (FITC) is a probe for the immunochemical detection of GST tags on recombinant proteins. Recombinant proteins are...
Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux
France
Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions
